Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-γ release by liver NKT cells

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1413-1422

  Trobonjaca, Z ^a   Leithauser F ^a   Moller P ^a   Schirmbeck, R ^a   Reimann, J ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; B7 ANTIGEN; CD1 ANTIGEN; CD11 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0035422520     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1413     Document Type: Article

References (70)

1. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury
2. + cells in the liver of mice
3. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
4. + natural T cells with distinct cytotoxic activitics and Th1, Th2, and Th0 cytokine secretion patterns
5. Natural T cells in the human liver: Cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Vα24-JαQ and γδ T cell receptor bearing cells
6. + cells originate from multiple pathways
7. Intensive expansion of natural killer cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation
8. Rapid death and regeneration of NKT cells in anti-CD3ε-or IL-12-treated mice: A major role for bone marrow in NKT cell homeostasis
9. + T cells for liver injury induced by Salmonella infection in mice
10. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria
11. Natural killer T cell activation inhibits hepatitis B virus replication in vivo
12. + T cells for concanavalin A-induced hepatic injury in mice
13. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis
14. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide
15. + T cells and rapid elimination of effector cells by apoptosis
16. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
17. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
18. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells
19. + NK T lymphocytes
20. + NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells
21. Potent expansion of human natural killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15
22. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
23. Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
24. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice
25. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
26. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice
27. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice
28. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
29. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-γ
30. Mechanisms of class I restricted immunopathology: A transgenic mouse model of fulminant hepatitis
31. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice
32. Manipulation of T cell responses with monoclonal antibodies
33. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
34. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes
35. Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo
36. + T lymphocytes but fail to promote survival
37. A subset of NKT cells that lacks the NKI.1 marker, expresses CD1d molecules, and autopresents the α-galactosylceramide antigen
38. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice
39. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells
40. Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: Involvement in interleukin-2-induced interleukin-12 and intefferon-γ production
41. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells
42. A pivotal role of IL-12 in Th1-dependent mouse liver injury
43. Innate and acquired activation pathways in T cells
44. Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-γ production
45. + T lymphocytes
46. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
47. IFNγ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12
48. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for 1FN-γ production
49. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development
50. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells
51. Defective NK cell activity and Th1 response in IL-18-deficient mice
52. Murine macrophages secrete interferon-γ upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation
53. + lymphoid dendritic cells
54. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-γ production by dendritic cells
55. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells
56. Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: The cytokine milieu of concanavalin A hepatitis
57. Liver allograft rejection: An overview of morphologic findings
58. Clinicopathological study of lymphocyte attachment to endothelial cells (endothelialitis) in various liver diseases
59. Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice
60. Interferon γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A
61. Strain difference in the induction of T-cell activation-associated, interferon γ-dependent hepatic injury in mice
62. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure
63. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis
64. Concanavalin A-induced liver cell damage: Activation of intracellular pathways triggered by tumor necrosis factor in mice
65. Concanavalin A hepatotoxicity in mice: Tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation
66. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection
67. Bimodal role of endogenous interleukin-6 in concanavalin A-induced hepatitis in mice
68. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors
69. Requirement of peptidergic sensory innervation for disease activity in murine models of immune hepatitis and protection by β-adrenergic stimulation
70. Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease